BioInsights - Vol 9 Issue 1

CELL AND GENE THERAPY INSIGHTS

February 2023 Issue

Vol 9 Issue 1

Download PDF

Featuring

Issue Spotlight: Preclinical & translational R&D
Scalability
Other articles
Webinars

SPOTLIGHT

Preclinical & translational R&D
Sven Kili
Guest Editor:
Sven Kili, CEO at Antion Biosciences

Interview

Assessing the evolving AAV preclinical safety landscape in 2023 & beyond

Assessing the evolving AAV preclinical safety landscape in 2023 & beyond

Basel Assaf
4 April
Read
Navigating the path to clinic for ATMPs: a regulator’s perspective

Navigating the path to clinic for ATMPs: a regulator’s perspective

James W McBlane
2 February
Read
Preclinical toolkit evolution for cancer vaccines & CAR-T cell therapy

Preclinical toolkit evolution for cancer vaccines & CAR-T cell therapy

Adam Snook
18 January
Read

Viewpoint

Preclinical safety assessment in therapeutic genome editing

Preclinical safety assessment in therapeutic genome editing

Roberto Nitsch
10 March
Read
Addressing gene therapy translational R&D bottlenecks in the CNS

Addressing gene therapy translational R&D bottlenecks in the CNS

Anindya Sen
9 March
Read
Key considerations when translating a cell therapy product into the clinic

Key considerations when translating a cell therapy product into the clinic

Anthony Ting
6 February
Read

Vectors FOCUS

Scalability

Interview

Sharing best practices in AAV vector scale-up

Sharing best practices in AAV vector scale-up

Seth Levy
16 January
Read

Podcast

Maximizing efficiency & flexibility in viral vector manufacturing scale-up

Maximizing efficiency & flexibility in viral vector manufacturing scale-up

D Kole, J Petrone, M Bisschops et al.
7 March
Listen

EBook

Analytical innovation: meeting the demands of commercial viral vector manufacture

Analytical innovation: meeting the demands of commercial viral vector manufacture

16 March
Read

Journal articles

Research Article

Advanced therapies, hospital exemptions & marketing authorizations: the UK’s emerging regulatory framework for point-of-care manufacture

Advanced therapies, hospital exemptions & marketing authorizations: the UK’s emerging regulatory framework for point-of-care manufacture

Edison Bicudo, Irina Brass
23 February
Read

Expert Insight

Implementing demand & operations planning in clinical cell & gene therapy

Implementing demand & operations planning in clinical cell & gene therapy

Peter Horton
26 January
Read

Innovator Insight

Enhancing non-viral gene editing, processing & expansion of T & NK cells

Enhancing non-viral gene editing, processing & expansion of T & NK cells

Sung Lee, Deepak Kumar
6 February
Read
Commercializing cell & gene therapies: a perspective from the quality function

Commercializing cell & gene therapies: a perspective from the quality function

Christoph Meyer, Andreas Wirth
9 February
Read
Simplifying lentiviral downstream processing with a novel affinity resin & robust analytical tools

Simplifying lentiviral downstream processing with a novel affinity resin & robust analytical tools

Chantelle Gaskin, Suzy Brown
27 February
Read

Interview

Next steps for MSC innovation

Next steps for MSC innovation

Jacques Galipeau
18 January
Read
Vaccines & beyond: a decade in mRNA delivery

Vaccines & beyond: a decade in mRNA delivery

Russell Johnson
30 January
Read
Seizing the day: addressing the urgent need for standards development in regenerative medicine

Seizing the day: addressing the urgent need for standards development in regenerative medicine

Richard McFarland
15 March
Read
Exploring the potential of insect cell lines for efficient AAV production

Exploring the potential of insect cell lines for efficient AAV production

20 March
Read

FastFacts

Technology innovation to address challenges in gene therapy manufacture

Technology innovation to address challenges in gene therapy manufacture

Tania D Pereira Chilima
10 March
Read

Viewpoint

Current trends in advanced therapy development & commercialization for rare diseases

Current trends in advanced therapy development & commercialization for rare diseases

Alan Boyd
28 February
Read

Infographic

Eureca-V™ Nuclease: the wild-type MAD7® CRISPR Type-V nuclease licensed from Inscripta®

Eureca-V™ Nuclease: the wild-type MAD7® CRISPR Type-V nuclease licensed from Inscripta®

17 January
Read

Poster

Optimizing vector production & purification to enhance scalable AAV manufacturing

Optimizing vector production & purification to enhance scalable AAV manufacturing

J Zmuda, J Molinari, J England
24 January
Read

Corrigendum

Corrigendum to: thinking ahead: developing biosynthetic blood to anticipate donor drought

Corrigendum to: thinking ahead: developing biosynthetic blood to anticipate donor drought

A Goldman, S Kilpatrick, M Madrid et al.
24 January
Read

Webinars